文献速递中毒与环境急症消化、代谢与肾脏急症

亚甲蓝治疗高铁血红蛋白血症的有效性与耐受性:单毒物中心二十四年经验

Effectiveness and tolerability of methylthioninium chloride (methylene blue) for the treatment of methemoglobinemia: twenty-four years of experience at a single poison center.
PubMed 文献 · Clin Toxicol (Phila) · 2025-03-10
一句话结论纽约市毒物中心24年185例数据显示,1-2 mg/kg亚甲蓝使98%高铁血红蛋白血症患者改善,归因不良反应4.9%。

该研究回顾纽约市毒物中心2000至2024年所有因高铁血红蛋白血症接受亚甲蓝治疗的病例,共纳入185例,采用描述性统计。中位高铁血红蛋白水平29%(IQR 19-42%),最常见涉及药物为挥发性亚硝酸盐(41%)、局部麻醉药(15%)和氨苯砜(11%)。中位亚甲蓝剂量1 mg/kg(IQR 1-2 mg/kg;范围0.5-4 mg/kg),11%接受多剂,中位总剂量2 mg/kg(IQR 2-3 mg/kg)。给药后98%病例报告改善(95%CI 96-100%),归因不良反应9例(4.9%;95%CI 4.6-5.1%),包括1例溶血。作者认为亚甲蓝有效且耐受良好,单剂1-2 mg/kg足以治疗大多数患者。

要点

  • 185例高铁血红蛋白血症患者中,亚甲蓝给药后98%报告改善(95%CI 96-100%)。
  • 中位亚甲蓝剂量1 mg/kg(IQR 1-2 mg/kg;范围0.5-4 mg/kg),11%接受多剂,多剂中位总剂量2 mg/kg(IQR 2-3 mg/kg)。
  • 归因于亚甲蓝的不良反应9例(4.9%;95%CI 4.6-5.1%),包括1例溶血。
  • 7例检测葡萄糖-6-磷酸脱氢酶活性的患者中2例缺乏,其中仅1例在亚甲蓝后未改善。
  • 2例死亡均与亚硝酸钠暴露相关;多剂治疗者多与挥发性亚硝酸盐(n=7)或氨苯砜(n=6)相关。

适用人群与场景

  • 2000至2024年报告至纽约市毒物中心、因高铁血红蛋白血症接受亚甲蓝治疗的病例,共185例。

处置流程与药物剂量

  • 亚甲蓝中位剂量1 mg/kg(IQR 1-2 mg/kg;范围0.5-4 mg/kg);11%病例接受多剂,多剂中位总剂量2 mg/kg(IQR 2-3 mg/kg)。

红旗征与不能漏的情况

  • 本系列2例死亡均与亚硝酸钠暴露相关。

研究设计与关键结果

  • 回顾性系列:185例因高铁血红蛋白血症接受亚甲蓝治疗者,中位高铁血红蛋白水平29%(IQR 19-42%)。
  • 涉及药物:挥发性亚硝酸盐41%、局部麻醉药15%、氨苯砜11%。
  • 亚甲蓝后改善98%(95%CI 96-100%);归因不良反应9例(4.9%;95%CI 4.6-5.1%),包括1例溶血。
  • 7例检测葡萄糖-6-磷酸脱氢酶活性者中2例缺乏,仅1例在亚甲蓝后未改善。
  • 接受多剂者中,多数与挥发性亚硝酸盐(n=7)或氨苯砜(n=6)相关。

证据类型、等级与局限

  • 证据类型:单毒物中心病例系列(2000至2024年),主要采用描述性统计。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,亚甲蓝对高铁血红蛋白血症患者有效且耐受良好,单剂1-2 mg/kg足以治疗大多数患者,支持当前治疗推荐。
  • 作者指出,尽管葡萄糖-6-磷酸脱氢酶活性检测例数少,归因于亚甲蓝的主要不良反应极为罕见。
  • 作者指出,接受多剂治疗的病例中相当比例与氨苯砜暴露相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Despite the widely accepted use of methylthioninium chloride (methylene blue) to treat methemoglobinemia, data regarding clinical outcomes are sparse. We sought to better elucidate the efficacy and tolerability of methylthioninium chloride.

METHODS: We identified all cases reported to the New York City Poison Center from 2000 to 2024 in which methylthioninium chloride was administered for methemoglobinemia. We extracted clinical data from these cases, which we assessed using primarily descriptive statistics.

RESULTS: A total of 185 cases were included. The median methemoglobin level was 29% (IQR: 19-42%). Implicated xenobiotics were most frequently volatile nitrites (41%), local anesthetics (15%), and dapsone (11%). The median methylthioninium chloride dose was 1 mg/kg (IQR: 1-2 mg/kg; range: 0.5-4 mg/kg). Multiple doses of methylthioninium chloride were administered in 11% of cases, with a median total dose of 2 mg/kg (IQR: 2-3 mg/kg), the majority of which were associated with volatile nitrites (n = 7) or dapsone (n = 6). Improvement after administration of methylthioninium chloride was reported in 98% of cases (95% CI: 96-100%). Adverse effects attributable to methylthioninium chloride were reported in nine cases (4.9%; 95% CI: 4.6-5.1%), including one instance of hemolysis. Glucose-6-phosphate dehydrogenase activity was found to be deficient in two of seven patients tested, only one of whom did not improve after methylthioninium chloride. Two deaths occurred in this series, both associated with sodium nitrite exposure.

DISCUSSION: Most patients with methemoglobinemia improved after 1-2 mg/kg of methylthioninium chloride, supporting current treatment recommendations. Despite few instances of glucose-6-phosphate dehydrogenase activity testing, major adverse effects attributable to methylthioninium chloride were extremely rare. A relatively large proportion of cases receiving multiple doses were associated with dapsone exposure.

CONCLUSIONS: In this series, methylthioninium chloride was both efficacious and well tolerated in patients with methemoglobinemia, with a single dose of 1-2 mg/kg being sufficient to treat most patients.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Rothenberg R, Biary R, Hoffman RS, et al. Effectiveness and tolerability of methylthioninium chloride (methylene blue) for the treatment of methemoglobinemia: twenty-four years of experience at a single poison center. Clin Toxicol (Phila). 2025. PMID: 40062661. doi:10.1080/15563650.2025.2470428

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。